Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Pulmonary hypertension:
travel, flying and high altitude

Many people with clinically stable pulmonary hypertension can travel, including by air, but travel should be planned with due consideration of disease severity, oxygenation and ongoing treatment. The main problem associated with flying and high altitude is reduced oxygen pressure: this may lower oxygen saturation, increase pulmonary vasoconstriction and place an additional load on the right ventricle.
For people who use oxygen or continuous infusions, or have more advanced disease, preparations must begin before departure.

Fitness to fly cannot be determined from pulmonary pressure alone. It is more important to establish whether pulmonary hypertension is stable, whether hypoxemia is present, which symptoms occur during exertion and how severely right heart function is impaired.

The main points to know are:


Why flying and high altitude can cause problems

The cabin of a standard commercial aircraft is not pressurized to sea-level conditions. During cruising, cabin pressure may correspond to an altitude of up to approximately 2,438 meters. In a healthy person, the reduction in oxygen is generally compensated for without difficulty; in pulmonary hypertension, it may cause greater oxygen desaturation and increased pulmonary vasoconstriction.

This effect is particularly relevant in patients who already have low oxygen saturation at sea level, coexisting lung disease or limited right ventricular reserve. ESC/ERS guidelines nevertheless indicate that brief hypoxic exposure is generally well tolerated by many patients with clinically stable PAH.
This does not mean that flying is automatically safe for everyone: available studies have predominantly included selected, stable patients.

When oxygen may be needed during a flight

ESC/ERS guidelines recommend supplemental oxygen during flights for patients already using it at sea level and for those with an arterial oxygen partial pressure below 60 mmHg or arterial oxygen saturation below 92%. In patients already receiving oxygen, requirements during a flight may be higher than usual.
The necessary flow rate should not, however, be decided independently: it must be agreed with the treating center and be compatible with equipment approved by the airline.

Some patients may benefit from a dedicated pre-travel assessment, particularly when oxygen saturation is borderline, there are associated respiratory diseases or a long flight is planned. Hypoxic challenge testing may be used in expert centers to assess the response to an oxygen concentration similar to that in the cabin, but it is not routinely required for every patient.

Airline rules governing portable oxygen concentrators, batteries and medical documentation are not uniform. The airline should therefore be contacted in advance to check which devices are accepted and what battery operating time is required for the entire journey, including possible waits or delays.

High altitude: why 1,500 meters is a precautionary threshold

For patients with PAH, European guidelines suggest avoiding altitudes above 1,500 meters without supplemental oxygen. This is a precautionary recommendation because the effects of many hours or days of hypoxia at altitude have not been studied as extensively as conditions at sea level.
It does not mean that danger suddenly appears at 1,501 meters while no risk exists at 1,499 meters: the response depends on altitude, duration of exposure, rate of ascent and the individual's condition.

Some small studies have shown that stable patients with PAH or CTEPH and without significant hypoxemia at low altitude may tolerate short excursions up to approximately 2,500 meters. Other studies, however, have documented a non-negligible number of altitude-related adverse events during longer exposures and a benefit from supplemental oxygen.
A short excursion lasting a few hours and a mountain stay lasting several days should therefore not be considered equivalent.

People with pulmonary hypertension associated with hypoxia or significant respiratory disease may have a different tolerance from someone with PAH and normal oxygen saturation. In these cases, the decision requires an even more individualized assessment.

Medications, infusions and documents to prepare

Essential medications should be carried in hand luggage, in quantities sufficient for the trip plus a reserve for possible delays. It is useful to carry an up-to-date treatment list, the diagnosis, contact details for the specialist center and, when necessary, a medical letter explaining the presence of medications, needles, pumps or oxygen concentrators.

Continuous infusion therapies require particular attention. Abrupt interruption of a parenteral prostacyclin can be dangerous. A spare pump, batteries, medication and necessary supplies should be arranged so that a malfunction or delay can be managed without interrupting treatment.
For international travel, it is useful to know in advance the location of a center experienced in pulmonary hypertension and to check healthcare access and insurance coverage.

When crossing several time zones, intervals between doses should not be changed by guesswork. For treatments requiring strict schedules or infusions, it is preferable to agree in advance with the treating team how to adjust administration times.

During a long journey: movement, fluids and thrombosis

During long periods of sitting, it is reasonable to move the feet and legs periodically and, when possible and safe, stand up for short walks. Hydration should follow the advice received: people taking diuretics or prone to fluid retention should not force themselves to drink large amounts of water based on the generic advice to "drink plenty".

Prolonged air travel modestly increases the risk of venous thromboembolism even in the general population, but having pulmonary hypertension does not automatically mean that anticoagulation must be started. Compression stockings or pharmacological prophylaxis may be appropriate only for certain risk profiles and must be decided individually.
In patients with chronic thromboembolic pulmonary hypertension, anticoagulation is already part of disease management and must not be changed for travel without medical advice.

Frequently asked questions about travel, flying and altitude

Can people with pulmonary hypertension fly?
Many clinically stable patients can fly, but the risk depends on disease severity and oxygenation. Before traveling, it is advisable to check with the treating center whether supplemental oxygen or a specific assessment is needed.

When is in-flight oxygen required?
ESC/ERS guidelines recommend in-flight oxygen for people who already use it at sea level and for patients with PaO2 below 60 mmHg or arterial oxygen saturation below 92%. The prescription must be individualized.

At what altitude is caution needed?
As a precaution, guidelines advise patients with PAH to avoid altitudes above 1,500 meters without supplemental oxygen, although some stable, non-hypoxemic patients have tolerated short exposures at higher altitudes.

Should pulmonary hypertension medications go in checked baggage?
Essential medications should preferably be kept in carry-on luggage, together with spare supplies and clinical documentation. Continuous therapies, such as certain infusions, require a specific plan and backup equipment.

Is anticoagulant treatment necessary solely because you are flying?
No. Anticoagulation should not be started on your own for a journey. Thrombosis prevention depends on individual risk and should be agreed with a physician when specific risk factors are present.

References
  1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237.
  2. Preston IR, Howard LS, Langleben D, et al. Management of pulmonary hypertension in special conditions. European Respiratory Journal. 2024;64(4):2401180. doi:10.1183/13993003.01180-2024.
  3. Schneider SR, Mayer LC, Lichtblau M, et al. Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial. ERJ Open Research. 2021;7(4):00314-2021. doi:10.1183/23120541.00314-2021.
  4. Schneider SR, Müller J, Bauer M, et al. Overnight exposure to high altitude in pulmonary hypertension: adverse events and effect of oxygen therapy. European Heart Journal. 2024;45(4):309-311. doi:10.1093/eurheartj/ehad789.
  5. Lichtblau M, Saxer S, Latshang TD, et al. Altitude Travel in Patients With Pulmonary Hypertension: Randomized Pilot-Trial Evaluating Nocturnal Oxygen Therapy. Frontiers in Medicine. 2020;7:502. doi:10.3389/fmed.2020.00502.
  6. Schneider SR, Lichtblau M, Furian M, et al. Cardiorespiratory Adaptation to Short-Term Exposure to Altitude vs. Normobaric Hypoxia in Patients with Pulmonary Hypertension. Journal of Clinical Medicine. 2022;11(10):2769. doi:10.3390/jcm11102769.
  7. Seccombe LM, Chow V, Zhao W, et al. Right heart function during simulated altitude in patients with pulmonary arterial hypertension. Open Heart. 2017;4(1):e000532. doi:10.1136/openhrt-2016-000532.
  8. Roubinian N, Elliott CG, Barnett CF, et al. Effects of commercial air travel on patients with pulmonary hypertension. Chest. 2012;142(4):885-892. doi:10.1378/chest.11-2016.
  9. Coker RK, Armstrong A, Church AC, et al. BTS Clinical Statement on air travel for passengers with respiratory disease. Thorax. 2022;77(4):329-350. doi:10.1136/thoraxjnl-2021-218110.
  10. Groth A, Saxer S, Bader PR, et al. Acute hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary hypertension. International Journal of Cardiology. 2018;270:262-267. doi:10.1016/j.ijcard.2018.05.127.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.